What You Should Know:
– Medable Inc., the leading technology platform for clinical trials, today announced Medable Studio, an all-in-one application for configuring, translating, validating, and launching eCOA Plus (eCOA, eConsent, Televisit, Sensors) into clinical trials.
– Studio is a no-code suite that simplifies the complex eCOA launch process, giving biopharmaceutical companies greater control and transparency for faster study go-live and earlier patient enrollment. Customers choose between self-service, full-service, or a combination of options, all providing increased time and cost efficiency.
Medable Studio: Revolutionizing Clinical Trial Design with Cutting-Edge Technology
Medable Studio is transforming the clinical trial design process by enabling protocol-fit study designs—previously requiring months of configuration and translation—to be created within hours. With an intuitive interface, Medable Studio empowers non-technical users to rapidly build and launch complex clinical trials, all while leveraging Medable’s cloud platform to ensure access to the latest capabilities. This technology-first solution disrupts the traditionally opaque, professional services-dependent eCOA industry by enhancing control, transparency, and speed.
Medable Studio offers a comprehensive suite of innovative functions, including:
– Point-and-Click Builder: Create assessments, instruments, and diaries quickly using features such as no-code formatting, live preview, branching rules, and globalization support for translations.
– Visual Schedule of Assessments Builder: Easily add assessments and instruments to a study schedule, configure standard visits, workflows, and notifications, as well as manage unscheduled and remote visits.
– Translation Workbench: Streamline translation processes and eliminate bottlenecks by managing all translations seamlessly. Edit only the necessary content for translation and import it back efficiently, saving time and resources.
– Content Library: Store assessments, instruments, translations, and locales in a single system, allowing for easy reuse across multiple studies.
Medable, ranked in the top 8% of software companies on the 2023 Inc. 5000, has successfully deployed its software-as-a-service platform in over 300 decentralized and hybrid clinical trials across 60 countries, serving more than one million patients and research participants globally. Customers using Medable Studio have achieved remarkable outcomes, including a 200% increase in enrollment speed and a 50% reduction in costs.
Medable Studio upends the traditional study build/test/launch process by streamlining it using intelligence and automation,” said Tim Smith, Medable Chief Technology Officer and co-founder. “With Medable Studio, timelines shift from weeks and months to just days. Customers describe Studio as a quantum leap in speed, scale, and quality, and empowers sponsors with complete visibility and control over the entire process.”
